Gly-L-Phe-L-Lys | 71227-74-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Gly-L-Phe-L-Lys
• 英文别名: GFK；Gly-Phe-Lys；(2S)-6-amino-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]amino]hexanoic acid
• CAS: 71227-74-2
• 化学式: C₁₇H₂₆N₄O₄
• 分子量: 350.418
• InChiKey: YLEIWGJJBFBFHC-KBPBESRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.2
• 重原子数：
  25
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  148
• 氢给体数：
  5
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  N-苄氧羰基甘氨酰-L-苯丙氨酸 、 benzyl N²-((benzyloxy)carbonyl)-L-lysine hydrochloride 生成 Gly-D-Phe-L-Lys 、 Gly-L-Phe-L-Lys
  参考文献：
  名称：

  The relative susceptibility to racemization of L- and D-residues in peptide synthesis

  摘要：

  DOI：

  10.1016/s0040-4039(01)81904-3

文献信息

• [EN] NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF<br/>[FR] LIEURS AUTO-IMMOLABLES NON LINÉAIRES ET CONJUGUÉS DE CEUX-CI
  申请人：SYNTHON BIOPHARMACEUTICALS BV

  公开号：WO2018069375A1

  公开（公告）日：2018-04-19

  The present invention relates to linker-drug compounds (LDs) and antibody-drug conjugates (ADCs) comprising a non-linear self-immolative linker, which is cleavable or transformable under appropriate conditions and which reduces the hydrophobicity of the antibody-drug conjugate.

  本发明涉及连接子-药物化合物（LDs）和抗体-药物偶联物（ADCs），包括一个非线性自消除连接子，该连接子在适当条件下可被裂解或转化，并减少了抗体-药物偶联物的疏水性。
• Water-Soluble CC-1065 Analogs and Their Conjugates
  申请人：Beusker Patrick Henry

  公开号：US20090318668A1

  公开（公告）日：2009-12-24

  This invention relates to novel analogs of the DNA-binding alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and their conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.

  这项发明涉及DNA结合烷基化剂CC-1065的新型类似物及其结合物。此外，该发明涉及用于制备上述剂和它们的结合物的中间体。这些结合物设计为在一个或多个激活步骤之后以及/或由结合物控制的速率和时间跨度下释放它们的（多种）荷载，以便选择性地传递和/或可控地释放一个或多个所述的DNA烷基化剂。这些剂、结合物和中间体可用于治疗以不良（细胞）增殖为特征的疾病。例如，这项发明的剂和结合物可用于治疗肿瘤。
• Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation
  申请人：Beusker Patrick Henry

  公开号：US20080311136A1

  公开（公告）日：2008-12-18

  This invention relates to compounds comprising one or more therapeutic and/or diagnostic moieties and one or more functional moieties linked together via one or more triazole-containing linkers and to their intermediates and methods of their preparation. The triazole-containing linker may optionally contain one or more conditionally-cleavable or conditionally-transformable moieties and one or more spacer systems in between said moiety/moieties and the one or more therapeutic and/or diagnostic moieties.

  本发明涉及一种化合物，其中包含一个或多个治疗和/或诊断基团，以及一个或多个功能基团，通过一个或多个三唑含链连接在一起，以及它们的中间体和制备方法。三唑含链连接物可以选择性地包含一个或多个有条件可裂解或有条件可转化的基团，以及一个或多个间隔系统，位于所述基团和一个或多个治疗和/或诊断基团之间。
• [EN] SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES<br/>[FR] ANALOGUES CC-1065 SUBSTITUÉS ET LEURS CONJUGUÉS
  申请人：SYNTARGA BV

  公开号：WO2009017394A1

  公开（公告）日：2009-02-05

  This invention relates to novel agents that are analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and their conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.

  本发明涉及一种与DNA-烷基化剂CC-1065类似的新型剂，以及它们的共轭物。此外，本发明涉及用于制备所述剂和它们的共轭物的中间体。共轭物被设计为在一个或多个激活步骤后释放它们的（多个）有效载荷和/或由共轭物控制的速率和时间跨度，以有选择地传递和/或可控释放一个或多个所述的DNA烷基化剂。这些剂、共轭物和中间体可用于治疗其特征为不受欢迎的（细胞）增殖的疾病。例如，本发明的剂和共轭物可用于治疗肿瘤。
• Conjugates of CC-1065 analogs and bifunctional linkers
  申请人：SYNTARGA BV

  公开号：US11052155B2

  公开（公告）日：2021-07-06

  This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.

  本发明涉及 DNA 烷基化剂 CC-1065 的新型类似物及其共轭物。此外，本发明还涉及制备上述制剂和共轭物的中间体。这些共轭物的设计目的是在一个或多个活化步骤之后和/或以共轭物控制的速率和时间跨度释放它们的（多重）有效载荷，以便选择性地递送和/或可控地释放一种或多种所述 DNA 烷化剂。这些制剂、共轭物和中间体可用于治疗以不希望的（细胞）增殖为特征的疾病。例如，本发明的制剂和共轭物可用于治疗肿瘤。